Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180) [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab in previously treated advanced esophageal/eg junction carcinoma completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Carcinoma
• Esophagogastric Junction Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Esophageal Carcinoma, Esophagogastric Junction Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-07-17